29 Jul, 14:54 - Indian

Nifty Midcap 100 57967.05 (0.78)

Nifty Pharma 23085.95 (1.43)

Nifty Next 50 67306.15 (0.80)

Nifty Bank 56157.55 (0.13)

Nifty Smallcap 100 18231.9 (0.93)

SENSEX 81236.09 (0.43)

Nifty IT 35371.05 (0.00)

Nifty 50 24792 (0.45)

29 Jul, 14:54 - Global

NIKKEI 225 40674.55 (-0.79)

HANG SENG 25524.46 (-0.15)

S&P 6449.75 (0.23)

LOGIN HERE

companylogoFortis Healthcare Ltd

You are Here : Home > Markets > CompanyInformation > Company Background
BSE Code : 532843 | NSE Symbol : FORTIS | ISIN : INE061F01013 | Industry : Healthcare |


Directors Reports

DIRECTORS' REPORT

Dear Members,

Your Directors have pleasure in presenting herewith the Twenty Ninth Annual Report of your Company along with the Audited Standalone and Consolidated Financial Statements and the Auditors' Report thereon for the Year ended March 31, 2025.

FINANCIAL RESULTS

The highlights of Consolidated Financial Results of your Company and its Subsidiaries are as follows:

(Rs. in Lakhs)

Particulars

Consolidated

Year ended March 31, 2025 Year ended March 31, 2024

1. Revenue from operations

778,275 689,292

2. Other income

6,694 3,825

3. Total income (1+2)

784,969 693,117

4. Expenses

(a) Purchases of medical consumable and drugs

183,807 160,325

(b) Changes in inventories of medical consumable and drugs

(788) 1,543

(c) Employee benefits expense

116,724 111,953

(d) Finance costs

18,441 13,095

(e) Professional charges to doctors

163062 145,951

(f) Depreciation and amortisation expense

38,561 34,250

(g) Other expenses

156,676 142,756

Total expenses

676,483 609,873

5. Net profit/(loss) from continuing operations before share in profit/(loss) of associates and joint ventures, exceptional items and tax (3-4)

108,486 83,244

6. Add: Share in profit of associate companies and joint ventures

1,152 951

7. Net profit/(loss) before exceptional items and tax (5+6)

109,638 84,195

8. Exceptional gain/(loss)

(8,934) 1,602

9. Profit/(loss) before tax from continuing operations (7+8)

100,704 85,797

10. Tax expense/(credit)

19,766 21,275

11. Net profit/(loss) for the period from continuing operations (9-10)

80,938 64,522

12. Profit/(loss) before tax from discontinued operations

- -

13. Tax expense of discontinued operations

- -

14. Net profit/(loss) for the period from discontinued operations (12-13)

- -

15. Net profit/(loss) for the period (11+14)

80,938 64,522

16. Profit/(loss) from continuing operations attributable to:

Owners of the Company

77,421 59,888

Non-Controlling Interest

3,517 4,634

17. Profit/(loss) from discontinuing operations attributable to:

Owners of the Company

- -

Non-Controlling Interest

- -

18. Other Comprehensive Income (including OCI relating to associates and joint venture) (after tax)

(352) 178

19. Other comprehensive Income/(Loss) attributable to:

Owners of the Company

(321) 224

Non-Controlling interest

(31) (46)

20. Total comprehensive Income/( Loss) (15+18)

80,586 64,700

21. Total comprehensive Income/(Loss) attributable to:

Owners of the Company

77,100 60,112

Non-Controlling interest

3,486 4,588

The highlights of financial results of your Company as a Standalone entity are as follows:

(Rs. in Lakhs)

Particulars

Standalone
Year ended March 31, 2025 Year ended March 31, 2024

Continuing Operations

1. Operating Income

144,589 118,142

2. Other Income

19,855 14,300

3. Total Income (1+2)

164,444 132,442

4. Total Expenditure (Excluding finance cost, depreciation & tax expenses)

119,038 98,861

5. Operating Profit (EBITDA) (3-4)

45,406 33,581

6. Finance Charges, Depreciation & Amortisation

22,450 18,290

7. Profit before exceptional items and tax (5-6)

22,956 15,291

8. Exceptional items

(11,514) 9,365

9. Profit before tax (7+8)

11,442 24,656

10. Tax Expenses

5,063 4,711

11. Net Profit for the year (9-10)

6,379 19,945

12. Share in profits of associate companies

- -

13. Profit for the year from continuing operations (11+12)

6,379 19,945

14. Discontinuing Operations

Profit/(Loss) before tax from discontinuing operations

- -

Tax expense of discontinuing operations

- -

Profit/(Loss) after tax and before minority interest from discontinuing operations

- -

Share in profits/(losses) of associate companies

- -

Profit for the year from discontinuing operations

- -

15. Profit for the year (13+14)

6,379 19,945

Other comprehensive income

(145) (33)

Total comprehensive income (15+16)

6,234 19,912

STATE OF COMPANY'S AFFAIR, OPERATING RESULTS AND PROFITS

For the financial year 2024-25, the Company reported a consolidated revenue from operations of Rs. 7,783 Crores compared to Rs. 6,893 Crores reported for FY 2023-24. Revenue from Hospital business stood at Rs. 6,528 Crores compared to Rs. 5,686 Crores reported during the corresponding previous year. Hospital business revenues contributed 84% approx. to the total consolidated revenue in FY 2024-25 as compared to 82% in FY 2023-24. Agilus Diagnostics Limited ("Agilus"), the diagnostic business of the Company, reported gross revenues of Rs. 1,407 Crores compared to Rs. 1,372 Crores in the previous financial year. Considering elimination of inter-company revenue (within the group), net revenue of Agilus was at Rs. 1,255 Crores compared to Rs. 1,207 Crores in FY 2023-24.

The growth in hospital business was led by 9% growth in ARPOB at Rs. 2.42 Crores per annum compared to Rs. 2.22 Crores per annum in FY 2023-24. The occupancy levels stood at 69 % in FY 2024-25 as compared to 65% in FY 202324. The Company's focus specialties comprising Oncology, Gastroenterology, Neurosciences, Renal Sciences, Orthopedics and Cardiac Sciences grew by 16% YoY and contributed 62% to the total hospital revenues, similar to 62% in FY24. Revenue from International business recorded growth of 13 % in FY 2024-25 to reach Rs. 539 Crores compared to Rs. 479 Crores in FY 2023-24.

The consolidated EBITDA of the Company stood at Rs. 1,655 Crores compared to Rs. 1,306 Crores for the previous corresponding year. EBITDA margin of the Company stood at 21.3 % versus 18.9% in FY 2023-24. Hospital business EBITDA for FY 2024-25 was at Rs. 1,381 Crores compared to Rs. 1,077 Crores reported for FY 2023-24. The EBITDA margin of the hospital business stood at 21.1% versus 18.9% in FY24.

The diagnostic business of the Company reported EBITDA of Rs. 274 Crores compared to Rs. 229 Crores reported in the corresponding previous year. The EBITDA margin of the diagnostic business stood at 19.5% versus 16.7% (basis gross revenue) for the year FY 2023-24.

Profit after tax for FY 2024-25 stood at Rs. 809 Crores compared to the PAT of Rs. 645 Crores in FY 2023-24. PAT includes an exceptional loss of Rs.89.3 Crores in FY 2024-25 primarily pertaining to impairment movement in an associate Company and impairment of assets in a subsidiary company, offset by gain of Rs.23.5 Cr related to the divestment of the Richmond Road, Bangalore facility in December 2024 and Rs.16.0 Crores in FY 2023-24 which pertains to the reversal of impairment in an associate company and profit related to the divestment of Chennai facilities.

The Company's net debt stood at Rs. 1,694 Crores as on March 31, 2025 compared to Rs. 264 Crores as on March 31, 2024 (net debt to equity of 0.18x versus 0.03x in FY24). Net debt to EBITDA stood at 0.93x as on March 31, 2025 as compared to the 0.17x as on March 31,2024 (basis Q4 annualized EBITDA).

As one of the leading, accredited, private healthcare chains in India, the Company strives to pursue the highest standards in patient care while endeavoring to achieve a superlative patient experience and high-quality clinical outcomes across its medical specialties. The Company's healthcare facilities are well supported by its investments in the state-of-the-art medical infrastructure and equipment enabling it to provide advanced treatment options to its patients. The Company's clinical and paramedical talent allow it to consistently promote high standards of tertiary and quaternary healthcare services in its key specialties such as Cardiac Sciences, Oncology, Neurosciences, Orthopedics, and transplants.

The Company has progressed well on the strategic priorities that it had outlined for itself in FY25. During the year 202425, the Company further strengthened its prime medical programs in key facilities across India with addition of several eminent clinicians in Neurology, Cardiac Sciences, Oncology, Gastroenterology, Orthopedics, and Gynecology. The Company augmented its medical infrastructure by commissioning Gamma Knife, MR LINAC, Surgical Robots, in some of its key facilities such as FMRI, FEHI, and others. FMRI is equipped with both Gamma Knife and MR-LINAC technologies under one roof, reaffirming the Company's commitment to offering the most advanced treatment options.

The Financial Year 2024-25 has witnessed good progress for Company's key growth levers, including inorganic growth, portfolio rationalization and brownfield bed expansion. As part of Company's inorganic growth strategy, Fortis through its wholly owned subsidiary signed definitive agreement in February 2025 to acquire Shrimann Superspecialty Hospital in Jalandhar, Punjab for Rs.462 crores. This acquisition will add 228 beds to Company's network and offers the potential to increase the facility's total capacity to over 450 beds. This transaction will allow to further strengthen Company's presence in Punjab region from approximately 800 beds to over 1,000 beds.

Continuing with the portfolio rationalization strategy, the Company has divested business operations of Richmond Road Hospital in Bangalore in December 2024. This is the third facility divested by the Company after the divestment of Malar facility and Vadapalani facility in Chennai.

In December 2024, the Company raised Rs. 1,550 crores through the issuance of non-convertible debentures. Leveraging these funds, along with internal accruals, the Company has consolidated its stake in Agilus by acquiring 31.52% stake from private equity investors. As a result, FHL now holds 89.20% equity stake in Agilus.

Recently, in April 2025, the Company has also successfully acquired the 'Fortis' brand and trademarks, for a consideration of Rs.200 crores.

The healthcare vertical of the Company primarily comprises day care specialty, diagnostics and tertiary and quaternary care. As of March 31, 2025, the Company had a network of 27 healthcare facilities in India with ~4,750 operational beds including beds under the O&M model.

There has been no change in the nature of business of the Company during the year under review. The Company continues its endeavor to provide quality healthcare services with an emphasis on high degree of clinical outcomes and an unparalleled patient experience (further information on Company performance is detailed in the Company section of the "Management Discussion and Analysis" in the Annual Report).

SIGNIFICANT MATTERS DURING THE YEAR UNDER REVIEW

The Company strategically reviewed and prioritised key areas to drive revenues and operational performance. These include aspects related to evaluating the current portfolio of the Company's facilities and planned bed expansion, initiating cost optimisation measures across the network, investing in technology and medical equipment and further strengthening its clinical excellence program. Details about which are mentioned in the Business Strategy section of the Management Discussion and Analysis Report ('MDA').

Further, the Board has from time to time during the year under review updated its stakeholders regarding the key developments that took place by disseminating necessary information to the stock exchanges and through various means of communications to the investors. Some of these key matters pertaining to previous years are mentioned below:

Post a successful bid, your Company had entered into share subscription Agreement dated July 13, 2018, for issuance of 235,294,117 Shares at a price of Rs.170 per share for an aggregate consideration upto Rs.4,000 Crores (Rupees Four Thousand Crores only) to Northern TK Venture Pte Limited ("NTK"), an indirect wholly owned subsidiary of IHH Berhad ('IHH'). Consequently, after obtaining regulatory and statutory approvals such as from Securities and Exchange Board of India, Competition Commission of India and in terms of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, IHH made Mandatory Open Offer for acquisition of upto 197,025,660 Equity Shares representing additional 26% of the expanded voting share capital of your Company ("Fortis Open Offer") and another Mandatory Open Offer for acquisition of up to 4,894,308 fully paid up equity shares of face value of Rs.10 each, representing 26% of the fully diluted voting equity share capital of Fortis Malar Hospitals Limited ("Fortis Malar Open Offer").

After the Preferential Allotment on November 13, 2018, public announcement was made on December 07, 2018 regarding Fortis Open Offer and Fortis Malar Open Offer, thereafter the Hon'ble Supreme Court of India had on December 14, 2018 passed an order ("Status Quo Order") directing "status quo with regard to sale of the controlling stake in Fortis Healthcare to Malaysian IHH Healthcare Berhad be maintained". In light of the Status Quo Order, Fortis Open Offer and Fortis Malar Open Offer were put on hold until further order(s)/clarification(s)/ direction(s) issued by the Hon'ble Supreme Court of India. Vide its order dated November 15, 2019, the Hon'ble Supreme Court had issued suo-moto contempt notice to, among others, your Company, and directed its Registry to register a fresh contempt petition in regard to alleged violation of the Status Quo Order ("Contempt Petition").

Petitions before the Hon'ble Supreme Court including the suomoto contempt have been disposed of vide judgement dated September 22, 2022 ("Judgement"). No finding of contempt has been made against either your Company, or its independent directors. Based on legal advice, the Company is of the clear view that the Status Quo Order dated 14th December 2018 no longer exists. Therefore, your Company is continuing to pursue actions which are in the best interest of its shareholders and itself. Our promoter is simultaneously seeking legal counsel for pursuing and securing the Open Offer.

In the Judgement, it has been stated by the Hon'ble Supreme Court that RHT Transaction appeared prima facie to be an acquisition of proprietary interest to subserve the business structure of the Company. It also passed certain directions inter alia, that the High Court of Delhi may consider issuing appropriate process and appointing forensic auditor(s) to analyze the transactions entered into between FHL and RHT and other related transactions. Your Company plans to strenuously object to any contemplation of a forensic given that in the Judgment, no wrongdoing by the Company had even been alluded to. The Company's stated position is that these transactions were done in compliance with applicable laws, post requisite corporate and regulatory approvals and necessary disclosures /announcements. Currently, Your Company, is vehemently opposing the application filed by Daiichi before the High court for appointment of forensic auditor.

OTHER RELEVANT MATTERS

Based on complaint filed by your Company with the Economic Offences Wing ("EOW") in November 2020 against the erstwhile promoters/erstwhile promoters group company in respect of certain transactions, First Information Report (FIR) was registered on July 03, 2021, against them. EOW is investigating the matter. The said Complaint is also being investigated by the Enforcement Directorate and the Company is co-operating and providing requisitioned documents/ information to it. Further, pursuant to the order dated February 17, 2018 of MCA, SFIO has been investigating into the affairs of your Company/its subsidiaries. The Company is co-operating in the said investigation.

Fortis Hospitals Limited had filed a civil suit for recovery of Rupees 52,019 Lakhs before Hon'ble Delhi High Court against the ex-promoters and certain entities which is sub-judice.

DIVIDEND AND TRANSFER TO RESERVES

The Board of Directors has recommended a final dividend of Rs.1 (One) per equity share at the rate of 10% of the face value of the shares of the Company for the year ended March 31, 2025, be paid subject to the approval of the shareholders, to those shareholders whose names appear in the register of members as on the record date in proportion to the paid up value of the equity shares. The record date for the purpose of dividend will be Friday, July 25, 2025.

Refer the Company's policy on Dividend Distribution available on the website of the Company at https://www.fortishealthcare. com/investors/policies-&-code/483

During the financial year ended March 31, 2025, no amount (previous year: nil) transferred to general reserves.

Further, the Statement of Changes in Equity is forming part of the Standalone and Consolidated financial statements.

MATERIAL CHANGES

There are no material changes and commitments, affecting the financial position of your Company which have occurred in FY 2024-25, except as disclosed in this Annual Report.

The following changes took place during the year under review:

1) Your Company has issued 1,55,000 (One lac and fifty- five thousand) listed, senior, secured, rated, redeemable Non-Convertible Debenture each having a face value of Rs.1,00,000/- (Indian Rupees One lac) and an aggregate value of up to Rs.1550,00,00,000/- (Indian Rupees One Thousand Five Hundred and Fifty Crores only) ("Debentures" or "NCDs") on a private placement basis to the eligible investors.

2) Your Company has acquired 5,970,149, equity shares as held by International Finance Corporation ("IFC"), 1,24,37,811 equity shares as held by NYLIM Jacob Ballas India Fund III LLC ("NJBIF") and 63,10,315 equity shares held by Resurgence PE Investments Limited (formerly known as Avigo PE Investments Limited) ("Resurgence") (representing 7.61%, 15.86% and 8.05% equity stake respectively) in Agilus Diagnostics Limited (a material subsidiary of the Company) from IFC, NJBIF and Resurgence respectively.

3) Material subsidiary i.e Fortis Hospitals Limited ("FHsL") of your Company has divested its business operations of Richmond Road facility, Bangalore in December 2024, to continue with the portfolio rationalization strategy.

4) Your Company through its material subsidiary i.e Fortis Hospotel Limited ("FHTL") has signed definitive agreements for the acquisition of entire business operations of Shrimann Superspecialty Hospital ("Shrimann Hospital") in Jalandhar, Punjab along with the underlying hospital land and the adjacent land thereto, as a part of Company's inorganic strategy.

5) Your Company has participated in the auction conducted on December 21, 2024, for 'Fortis' brand and allied trademarks, by the Court appointed auctioneer, wherein your Company was declared as the successful bidder and Bid price was Rs.200 Crores.

STATEMENT IN RESPECT OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO THE FINANCIAL STATEMENTS

Statutory Auditors in their report to the Board of Directors on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("The Act") have given the opinion that the Company and such companies incorporated in India which are its subsidiary companies have, in all material respects, adequate internal financial controls with reference to consolidated financial statements and the financial statements of the Company and such internal financial controls were operating effectively as at March 31, 2025, based on the internal financial controls with reference to consolidated financial statements and the financial statements of the Company, criteria established considering the essential components of such internal controls stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. The Auditor's opinion on adequacy and operating effectiveness of internal control is self-explanatory.

DETAILS OF SUBSIDIARY/JOINT VENTURES/ASSOCIATE COMPANIES

During the year, the Company acquired an additional 31.52% equity stake (existing 57.68% equity stake) in Agilus Diagnostics Limited, comprising 2,47,18,275 equity shares. This acquisition was made from private equity investors, including Resurgence PE Investments Limited (formerly known as Avigo PE Investments Limited) - 63,10,315 shares, International Finance Corporation - 59,70,149 shares, and NYLIM Jacob Ballas India Fund III LLC - 1,24,37,811 shares.

Further note that your Board of Directors have adopted a policy for determining "material subsidiary" pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI (LODR) Regulations, 2015/SEBI Listing Regulations"). The said policy is available at https://www. fortishealthcare.com/investors/policies-&-code/483

In terms of the said policy, as on April 01, 2025, Fortis Hospitals Limited (FHsL), International Hospital Limited (IHL), Fortis Hospotel Limited (FHTL) and Agilus Diagnostics Limited (ADL) are considered as Material Subsidiary(ies). Necessary compliances w.r.t. material subsidiaries have been duly carried out in accordance with Regulation 24(1) of the SEBI Listing Regulations. The copies of the Secretarial Audit Reports of the material subsidiaries issued by the Company Secretary in Practice forms part of this report.

Further, no subsidiary/Joint venture/ Associate Companies has been added or ceased during the period under review except the increase in the shareholding Agilus Diagnostics Limited as disclosed above.

PERFORMANCE AND FINANCIAL POSITION OF EACH OF THE SUBSIDIARIES, ASSOCIATES AND JOINT VENTURE COMPANIES

The consolidated financial statements of your Company and its subsidiaries, prepared in accordance with applicable accounting standards, issued by the Institute of Chartered Accountants of India, forms part of the Annual Report. In terms of the Section 136 of the Companies Act, 2013, financial statements of the subsidiary companies are not required to be sent to the members of the Company. Your Company will provide a copy of separate annual accounts in respect of each of its subsidiary to any shareholder of the Company who asks for it and said annual accounts will be available for inspection and are also available on the website of the Company. Performance and financial position of each of Subsidiaries, Associates and Joint Ventures included in the Consolidated Financial Statements of your Company is enclosed herewith as "Annexure - I" in the prescribed format (Form AOC-1).

The contribution of the subsidiary/associates/joint venture companies to the overall performance of your Company is outlined in Note No. 26 of the Consolidated Financial Statements for the year ended March 31,2025.

LOANS/ADVANCES/INVESTMENTS/GUARANTEES

Particulars of Loans/Advances/Investments/guarantees given and outstanding during the FY 2024-25 forms part of the Notes to the Financial Statements.

PUBLIC DEPOSITS

During the financial year under review, your Company had not invited or accepted any deposits from the public, pursuant to the provisions of Section 73 of the Companies Act, 2013 read with the Companies (Acceptance of Deposit) Rules, 2014 and therefore, no amount of principal or interest was outstanding in respect of deposits from the Public as of the date of Balance Sheet.

UTILISATION OF FUNDS

The details of utilisation of funds earlier raised through preferential allotment are mentioned in Notes to Financial Statements. During the year under review, no preferential allotment was made by the Company for the equity shares.

Your Company has issued 1,55,000 (One lac and fifty-five thousand) listed, senior, secured, rated, redeemable NonConvertible Debenture each having a face value of Rs.1,00,000/- (Indian Rupees One lac) and an aggregate value of up to Rs.1550,00,00,000/- (Indian Rupees One Thousand Five Hundred and Fifty Crores only) ("Debentures" or "NCDs") on a private placement basis to the eligible investors to acquire an additional 31.52% equity stake in Agilus Diagnostics Limited. The details of utilisation of funds are mentioned in Notes to Financial Statements.

AUDITORS

M/s B S R & Co. LLP, (Registration No. 101248W/W- 100022), Chartered Accountants, were re-appointed as Statutory Auditors of your Company, by the shareholders in the 28th Annual General Meeting held on August 2, 2024 for a second term of four years i.e. up to the conclusion of the Annual General Meeting to be held in the year 2028.

The Notes on financial statements referred to in the Auditors' Report are self-explanatory and do not call for any further comments. The Auditors' Report does not contain any qualification, reservation or adverse remark. However, the Statutory Auditors have, in their report to the Board of Directors on the consolidated financial statements of the Company made the following comments which are self- explanatory and are categorised as "Emphasis of Matter", hence no comments in this regard have been offered by your Board of Directors:

a) Note 27 and 28 of the consolidated financial statements which deals with various matters including the ongoing investigation by Serious Fraud Investigation Office ("SFIO on Fortis Healthcare Limited and its subsidiaries regarding alleged improper transactions and non-compliances with laws and regulations including Companies Act, 2013 (including matters relating to remuneration paid to managerial personnel). These transactions and noncompliances relate to or originated prior to take over of control by reconstituted board of directors of Fortis in the year ended March 31,2018. As mentioned in the note, the Group has been submitting information required by SFIO and is also cooperating in the regulatory investigations.

b) As explained in the said note, the Group had recorded significant adjustments/provisions in its books of account during the year ended March 31,2018. The Company had launched legal proceedings and also filed a complaint with the Economic Offences Wing ('EOW') against erstwhile promoters and their related entities based on the findings of the investigation conducted by the Group. Further, based on management's detailed analysis and consultation with external legal counsel, a further provision has been made and recognised in the year ended March 31, 2021 for any contingency that may arise from the aforesaid issues. As per the management, any further financial impact, to the extent it can be reliably estimated as at present, is not expected to be material.

c) Note 30A of the consolidated financial statements relating to the order dated September 22, 2022 of the Hon'ble Supreme Court, whereby it has directed the Hon'ble High Court of Delhi inter alia that it may also consider issuing appropriate process and appointing forensic auditor(s) to analyse the transactions entered into between the Company and RHT Health Trust and other related transactions. The above-mentioned Note also states that the Hon'ble Supreme Court has observed that prima facie, it appears to be acquisition of proprietary interest of RHT Health Trust by the Holding Company are to subserve the business structure of the Holding Company.

Further, as per the requirement of Companies Auditor Report Order (CARO), Rules, 2016, there was no fraud other than as disclosed pertaining to earlier years reported by the above stated auditors during the year under review.

Cost Auditor

Pursuant to Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014, the cost audit records maintained by your Company in respect of its hospital activity is required to be audited. Your Directors had, on the recommendation of the Audit Committee and the Board of Directors, appointed M/s. Jitender, Navneet & Co., (Firm Registration No.: 000119), Cost Auditors to audit the cost accounts of your Company for the FY 2024-25 at a remuneration of Upto Rs.2,95,000/- (Rupees Two Lakhs Ninety Five Thousand only) plus applicable taxes and reimbursement of out-of-pocket expenses incurred in connection with the cost audit. As required under the Companies Act, 2013, the remuneration payable to the Cost Auditors is required to be placed before the Members in a general meeting for ratification. Accordingly, a resolution seeking member's ratification for the remuneration payable to M/s Jitender, Navneet & Co., Cost Auditors is included in the Notice convening the ensuing Annual General Meeting. Further, in terms of the Companies (Accounts) Rules, 2014, it is confirmed that maintenance of cost records as specified by the Central Government under sub-section (1) of Section 148 of the Companies Act, 2013, is applicable on your Company and accordingly such accounts and records are properly made and maintained.

The Report of the Cost Auditors for the FY 2023-24 does not contain any qualifications, reservations or adverse remarks and the comments given by the Cost Auditors are self- explanatory and hence do not call for any further explanations or comments.

Secretarial Auditor

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, M/s. Neelam Gupta & Associates, Company Secretaries (Firm Registration No. S2006DE086800), was appointed by the Board as the Secretarial Auditors of the Company for the Financial Year 2024-25. Further, the Company has recommended the appointment of M/s. Neelam Gupta & Associates, Company Secretaries for a term of 5 (five) consecutive years commencing from Financial Year April 1, 2025 to March 31, 2030, to undertake secretarial audit of the Company.

Accordingly, a resolution seeking appointment and fixation of fees of Secretarial Auditors of the Company is included in Notice convening the ensuing Annual General Meeting.

Further, M/s Neelam Gupta & Associates, Company Secretaries, has also submitted her consent to act as the Secretarial Auditors of the Company and have confirmed that they fulfil the criteria as specified in clause (a) of Regulation 24A(1A) of SEBI Listing Regulations and further confirmed that they have not incurred any of disqualifications as specified by the Securities and Exchange Board of India.

Further, pursuant to the provisions of Regulation 24A, the secretarial audit report of the Company and its material subsidiaries are attached as "Annexure- II" and "Annexure- II(A)" respectively. Further, the Report of the Secretarial Auditor for the FY 2024-25 does not contain any qualification, reservation or adverse remarks. The Secretarial Audit Report confirms that the Company has complied with the provisions of the Act, Rules, Regulations and Guidelines and that there were no deviations or non compliances.

Internal Auditors

The Company has a well-established, independent and in-house Internal Audit function that is responsible for providing assurance on compliance with operating systems, internal policies and legal requirements, as well as suggesting improvements to systems and processes. The

Internal Audit function monitors and evaluates the efficiency and adequacy of internal control systems in the Company.

The Head of Internal Audit reports functionally to the Audit Committee. Key internal audit findings are presented to the Audit Committee.

For FY25, Internal Audit(s) were performed in accordance with the Internal Audit plan approved by the Audit Committee.

In addition to the internal IA team conducting audit(s) covering key business processes as per approved plan, Deloitte Touche Tohmatsu India LLP and Grant Thorton Bharat LLP were engaged as an external service provider to perform Internal Audit for specific processes.

Compliance of Secretarial Standard

During the period under review, your Company has complied with the applicable provisions of Secretarial Standards issued by the The Institute of Company Secretaries of India.

SIGNIFICANT & MATERIAL ORDERS PASSED BY THE REGULATORS

During FY 2017-18 the Company, the Securities and Exchange Board of India (SEBI), initiated investigation w.r.t. siphoning of approx. Rs.5 Billion by its ex-promoters. Post investigation, SEBI had issued two Show Cause Notices i.e., dated November 12, 2020 (SCN 1) and April 9, 2021 (SCN 2), respectively.

A Show-Cause Notice (SCN- 1) was issued by SEBI to various entities including the Company and FHsL on November 20, 2020. In the SCN- 1, it was inter-alia alleged that the consolidated financials of the Company at the relevant period were untrue and misleading for the shareholders of the Company and the Company had circumvented certain provisions of the SEBI Act, Securities Contracts (Regulation) Act, 1956, and certain SEBI regulations. In response, a joint representation/reply was filed by the Company and FHsL on December 28, 2020 praying for quashing of the SCN- 1 by inter alia reiterating that the Company and FHsL, were in fact victims of the schemes of the Erstwhile Promoters (Malvinder Mohan Singh and Shivinder Mohan Singh) and justice, equity and fairness demands that the victim ought not be punished for the offences of the wrongdoers. All acts impugned in the SCN- 1 relate to the period when the Erstwhile Promoters controlled the affairs of Company and FHsL and the erstwhile Promoters are no longer involved in the affairs of the Company and FHsL. The Erstwhile Promoters were responsible for financial misrepresentation and not the Company and FHsL. Post resignation of the Erstwhile Promoters in February 2018, the Board of Directors of the Company, solely comprising Independent Directors looked after its welfare.

The new promoter of the Company (i.e. NTK Venture Pte. Ltd.) assumed control of the Company pursuant to a preferential allotment, which was approved by both Competition Commission of India and SEBI, which approved the open offer that had got triggered pursuant to such preferential allotment. Any adverse orders against the Company and FHsL would harm their existing shareholders, employees and creditors. The Company and FHsL have taken substantial legal actions against the Erstwhile Promoters and significant steps to recover the diverted amounts. SEBI passed an order dated 19.04.2022 w.r.t SCN -1 directing the Company & FHsL to pursue the measures taken to recover the amount of Rs.397.12 Crores (approx.) along with the interest from Erstwhile Promoters; & Audit Committee to regularly monitor the progress of such measures and report the same to board of directors at regular intervals. SEBI had imposed a penalty of Rs.50 lakh and Rs.1 Crore on FHsL and the Company respectively.

On April 09, 2021, SEBI issued another Show cause notice (SCN - 2) to various noticees including Escorts Heart Institute and Research Centre Limited ("EHIRCL"). In the said show cause notice, with respect to EHIRCL, it was alleged that Rs.567 crore was lent by the Company to EHIRCL in 2011, which was subsequently transferred by EHIRCL to Lowe Infra and Wellness Private Limited ("Lowe") in multiple transactions for the purchase of a land parcel. This land parcel, which was allegedly indirectly to be acquired by the Company through its subsidiary EHIRCL and another entity Lowe, was then transferred to RHC Holdings Private Limited ("RHC Holdings"). It was stated in the said Show cause notice that a structured rotation of funds was carried out to portray that the loan extended by the Company for the purchase of land had been paid back with interest in the year 2011. It is alleged that the Company was actually paid back by RHC Holding over a period of four years ending on July 31, 2015. In this respect, the Company and FHsL funds were allegedly routed through various layers in order to camouflage the transactions, and to circumvent legal provisions with respect to related party transactions.

In the Show cause Notice dated April 09, 2021 EHIRCL had been clubbed along with the other noticees, and had been painted with the same brush as the other noticees in alleging that certain noticees, including EHIRCL, were part of a fraudulent and deceptive device wherein they acted in fraudulent manner which led to the misuse and/or diversion of funds from a listed company i.e. FHL, amounting to approximately Rs.397.12 crore for the ultimate benefit of RHC Holdings and the erstwhile promoters. Thereby, it is alleged that EHIRCL has aided and abetted the routing of funds from the Company, ultimately to RHC Holdings, for the benefit of the promoter entities.

Further, after adjudicating the Show Cause Notice dated April 09, 2021, SEBI passed an order dated 18.5.2022 wherein it held that EHIRCL is responsible for fraudulent scheme perpetrated at the behest of the then management of FHL/FHsL for the benefit of their then promoters and therefore has violated the relevant provisions of SEBI (PFUTP) Regulations. SEBI acknowledged the fact that EHIRCL working under a completely new management presently and the said revamped management has already taken steps against the erstwhile promoters for the fraud perpetrated under their watch, shall serve as a mitigating factor while computing the penalty under section 15HA of the SEBI Act. Having said this, SEBI vide order dated 18.5.2022 imposed a penalty of Rs.1 crore on EHIRCL for violation of certain provisions of SEBI laws. The reasoning that was adopted for imposition of penalty on EHIRCL appears to be exactly on the same lines as the reasoning in the case of FHL and FHsL.

SEBI vide order dated May 18, 2022, passed in the Show Cause Notice dated April 09, 2021, imposed a penalty of Rs.1 (one) Crore on EHIRCL after finding that there has been violation of certain provisions of SEBI laws. While imposing the said penalty, SEBI acknowledged that EHIRCL working under a completely new management presently and the said revamped management have already initiated civil and criminal actions against the erstwhile promoters for the fraud perpetrated under their watch.

Both the orders dated 19.4.2022 and 18.5.2022 passed by SEBI have been appealed against by the Company, FHsL and EHIRCL before Securities Appellate Tribunal, Mumbai ("SAT"). On deposit of 50% of the penalty amount, in respect of FHSL & FHL, recovery of total penalty amount has been stayed and in respect of EHIRCL, operation of SEBI Order 18.5.2022 has been stayed. Appeals are pending adjudication.

During the Financial Year, Hon'ble High Court of Delhi on October 29, 2024 directed the Learned Joint Registrar - High Court of Delhi to conduct auction of 'Fortis' brand and allied trademarks. In the auction conducted on December 21, 2024 by the Court appointed auctioneer, only your Company participated and was declared as the successful bidder. Bid price was Rs.200 Crores. Owner of brand 'Fortis' had objected to the valuation of brand and the auction process. However, the Hon'ble Court vide its order dated March 25, 2025 confirmed the sale of brand 'Fortis' in favor of your Company. As per bid condition, your Company has deposited Rs.200 Crore with the Registrar General - High

Court of Delhi. Applicable GST, if any, will be over & above the bid amount and will be paid at a later stage. Learned Joint Registrar- High Court of Delhi vide its order dated April 04, 2025 has issued "Certificate of Sale" in favour of your Company.

CAPITAL STRUCTURE/STOCK OPTION

During the year under review, there is no change in the capital structure of the Company and no further stock options were granted under Employee Stock Option Plan 2007 and Employee Stock Option Plan 2011.

The Company currently manages its stock options through "Employee Stock Option Plan 2007" and "Employee Stock Option Plan 2011" ("Schemes") as approved by the shareholders. The Nomination and Remuneration Committee of the Board of Directors of the Company, inter alia, administers and monitors the Schemes of the Company. Each option when exercised would be converted into one fully paid up equity share of Rs.10 each of the Company. During the year under review, no option was granted by the Company. Disclosure pursuant to the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 for the year ended March 31, 2025 is available at the website of the Company at https://www.fortishealthcare.com/investors/annual-reports/476.

The certificate from the Secretarial Auditors of the Company stating that the Schemes have been implemented in accordance with the SEBI Regulations would be placed at the ensuing Annual General Meeting for inspection by members.

The Company has not made any provision of money for purchase of, or subscription for, its own shares or of its holding Company.

Details pertaining to shares in suspense account are specified in the report of Corporate Governance forming part of the Board Report.

ANNUAL RETURN

Pursuant to Section 92(3) read with Section 134(3)(a) of the Act, the Annual Return as on March 31, 2025 is available on the Company's website at https://www.fortishealthcare.com/ investors/annual-return/479

ENERGY CONSERVATION, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE

The particulars required under Section 134(3)(m) of the Companies Act, 2013, read with Rule 8(3) of the Companies (Accounts) Rules, 2014, regarding Conservation of Energy and Technology Absorption, is given in "Annexure - III", forming part of the Board's Report. Further, details pertaining to Foreign Exchange Earnings and Outgo is as given below:

TOTAL FOREIGN EXCHANGE EARNED AND USED (BASED ON STANDALONE FINANCIAL STATEMENTS)

(Rs. in Crores)

Particulars

Amount

Foreign Exchange earned in terms of Actual Inflows

14.02

Foreign Exchange outgo in terms of Actual Outflows

5.36

Note: Earning and expenditure in foreign currency is on accrual basis.

CORPORATE SOCIAL RESPONSIBILITY - OUR JOURNEY THROUGH THE PAST YEAR

The CSR Policy (approved by the Board of Directors) approaches this area under the philosophy that the Company's efforts should strive towards building and sustaining healthier humanity and fostering the holistic well-being of communities. The policy elucidates the concept of growing our business in a socially and environmentally responsible manner through an active role in empowering communities and driving social development and positive change.

The policy has defined the roles and responsibilities associated with governance and administration of design and implementation of initiatives. It further clarifies the criteria for identifying eligible programmes, mechanisms for monitoring, evaluation and as well as reporting and disclosure requirements. As an enterprise in the critical domain of healthcare, the Company has participated and implemented various socially responsive programs since its inception. These programs are consistent with the themes outlined in the relevant Acts as well as the CSR policy of the organisation.

The policy as approved by the Board is available on the Company's website at: https://www.fortishealthcare.com/ investors/policies-&-code/483

During the year, the Company engaged Sattva Media and Consulting Pvt. Ltd. ("Sattva Consulting") as an external agency/advisor for undertaking CSR activities of the Company and its subsidiaries for the financial year 2024-2025. Further, Sattva Consulting is engaged in the business of, inter alia, providing consultancy services in the social impact sector and implementation of corporate social responsibility programmes/ initiatives.

This year Company and its subsidiaries contributed their CSR Fund to the Apprenticeship training, Whole School Transformation (School Infrastructure Upgrade), PHC Upgradation, Scholarship to MBBS students, Cancer Screening Camps and Upgrading Health and Wellness Centers, and the Digital Health Training as highlighted in the table shown below:

Qualifying Amount & Spent during the FY 2024-25

(Amt in (Rs.))

Particulars

FHL FHTL IHL TOTAL

FY 2024-25 (Qualifying amount)

Rs.1,47,00,603 Rs.6,08,51,293 Rs.3,09,77,433 Rs.10,65,29,329

Total(A)

Rs.1,47,00,603 Rs.6,08,51,293 Rs.3,09,77,433 Rs.10,65,29,329

Spent for

Smart Health and Wellness Center (HWC) & Cancer Screening Camps - FICCI

Rs.52,10,437 Rs.52,10,437

Primary healthcare center (PHC) upgradation - Society of Community Health Oriented Operational Links (SCHOOL)

Rs.1,45,00,000 Rs.55,00,000 Rs.2,00,00,000

Digital Health Training - NATHealth

Rs.5,00,000 Rs.5,00,000

Whole School Transformation (School infrastructure upgrade) - YUVA Unstoppable

Rs.3,75,00,000 Rs.3,75,00,000

Scholarships to MBBS Students - Foundation for Excellence

Rs.50,00,000 Rs.50,00,000

Apprenticeship Program - Direct Implementation

Rs.1,37,91,859 Rs.77,69,877 Rs.1,48,08,356 Rs.3,63,70,092

Consultancy Fee - Sattva Consulting

Rs.4,08,744 Rs.10,81,416 Rs.4,58,640 Rs.19,48,800

Total (B)

Rs.1,47,00,603 Rs.6,08,51,293 Rs.3,09,77,433 Rs.10,65,29,329

Report pursuant to Clause O of Sub-Section 3 of Section 134 of the Companies Act, 2013 read with Rule 9 of Companies (Corporate Social Responsibility) Rules, 2014 is given in "Annexure IV".

DIRECTORS AND KEY MANAGERIAL PERSONNEL

The Board of Directors of your Company as on date of this report comprises Eleven (11) directors, of which one (1) is a Managing Director and CEO (Executive Director), four (4) are Independent Directors [including two (2) Women Directors] and rest of the six (6) directors are Non- Executive & NonIndependent Directors. In accordance with the provisions of Section 152 of the Companies Act, 2013 and the Articles of Association of the Company, Mr. Tomo Nagahiro and Mr. Lim Tsin Lin, Non-Executive Non- Independent Directors are liable to retire by rotation at the ensuing Annual General Meeting and have offered themselves for re-appointment. On the recommendation from Nomination & Remuneration Committee, the Board has recommended their re-appointment as the directors liable to retire by rotation.

As required under Regulation 36 of SEBI LODR and Secretarial Standards information or details of Mr. Tomo Nagahiro and Mr. Lim Tsin Lin, Non-Executive Non- Independent Directors, are provided in the Notice convening the ensuing Annual General Meeting.

The re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director (Designated as 'Managing Director & CEO') of the Company has been approved by the shareholders in the 28th Annual General Meeting held on August 02, 2024, effective from March 19, 2025 for a period of 2 years.

During the year under review, Mr. Ravi Rajagopal resigned from the Directorship & Chairmanship of the Company w.e.f. September 30, 2024.

Consequent to the resignation of Mr. Ravi Rajagopal as Chairman of the Company w.e.f. September 30, 2024, Mr. Indrajit Banerjee was appointed as the regular Chairman w.e.f. October 1, 2024, till the time vacancy is filled.

Mr. Leo Puri was appointed as an Additional Non-Executive Independent Director of the Company w.e.f. December 27, 2024 and had also been designated as Chairman of the Board. Consequently, Mr. Indrajit Banerjee has passed on the position of the Chairman to Mr. Leo Puri and continued being a member of the Board as an Independent Director.

Further pursuant to the Regulation 17(1)(c) of the SEBI (LODR) Regulations, 2015, the Company obtained the approval of shareholders confirming the appointment of Mr. Leo Puri as Non-Executive Independent Director of the Company vide postal ballot on March 20, 2025.

No director of the Company was disqualified to become/ continue as Director of the Company, in terms of the provisions of the Companies Act, 2013 and the rules made thereunder.

There is no inter-se relationship between the Board Members.

During the FY 2024-25, Ten (10) meetings were held by the Board of Directors. The details of board/committee meetings and the attendance of Directors are provided in the Corporate Governance Report.

Details of Key Managerial Personnel are as under:

Name

Designation

Dr. Ashutosh Raghuvanshi

Managing Director and Chief Executive Officer

Mr. Vivek Kumar Goyal

Chief Financial Officer

Mr. Satyendra Chauhan

Company Secretary & Compliance Officer

Disclosures regarding the following are mentioned in report on Corporate Governance forming part of this report.

1. Composition of Committee(s) of the Board of Director and other details;

2. Details of establishment of Vigil Mechanism;

3. Details of remuneration paid to all the Directors including Stock options; and

4. Commission received by Independent Directors; if any. BOARD EVALUATION

Pursuant to the provisions of Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board and the respective committees are required to carry out performance evaluation of the Board as a body, the Directors individually, Chairman as well as that of its Committees.

The Nomination of Remuneration Committee ("NRC") and the Board have laid down the manner in which formal annual evaluation of the performance of the Board, it's committees and individual directors is required to be made.

The following process of evaluation was approved by the Nomination and Remuneration Committee and the Board of Directors:

Sr. No. Process

Remarks

Criteria for Evaluation (including Independent Directors)

1. Kick Off Board Evaluation Program

The NRC Chairperson kick starts the process. The relevant questionnaires were circulated to the Board members.

2. Evaluation forms

The feedback so received from the members on the process was collated by Chief Human Resource Officer (CHRO).

This includes Board focus (Strategic inputs), Board Meeting Management, suggestions to improve Board performance Board Effectiveness Management Engagement, governance, risk management and addressing of follow up requests.

3. Evaluation by the Board and of Independent Directors

A compilation of the individual self-assessments was placed at the meeting of the Board of Directors to review collectively.

This includes demonstration of integrity, commitment, attendance at the meetings, contribution and participation, professionalism, contribution while developing Annual Operating Plans, demonstration of roles and responsibilities, review of high risk issues & grievance redressal mechanism, succession planning, Effectiveness of Board Committees etc.

4. Final recording and reporting

Based on the findings of the assessment, CHRO circulated a report to the Board members for further discussion and action planning. Based on the above, a final report on Board Evaluation 2024-25 was presented at a meeting of the Board of Directors held in May 2025.

The report includes key highlights, a presentation of an analysis of each response, actionable insights and comments.

MANAGERIAL REMUNERATION

Details pertaining to Remuneration as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

(a) The Ratio of the Remuneration of each Director to the median remuneration of the Employees of the Company for the FY 2024-25* along with the percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, during the financial year under review:

Nam ne of the Director

Designation

Remuneration of Director/ KMP for FY 2024-25 (Rs. in Crores) Median Remuneration of Employees (Rs. in Crores) Ratio of remuneration of each Director to the median remuneration of the employees % Increase/ Decrease in remuneration in FY 2024-25

1. Dr. Ashutosh Raghuvanshi*

Managing Director and Chief Executive Officer

9.59 220.97:1 6.00% !

2. Mr. Ravi Rajagopal**

Chairman (Independent Director)

0.51 11.75:1 NA

3. Mr. Dilip Kadambi#

Non-Executive Director

0.10 2.30:1 0.00%

4. Mr. Indrajit Banerjee#

Independent Director

1.05 24.19:1 5.00%@

5. Ms. Shailaja Chandra#

Independent Director

1.05 24.19:1 5.00%@

6. Ms. Suvalaxmi Chakraborty#

Independent Director

0.94 21.66:1 5.62%@

7. Mr. Mehmet Ali Aydinlar#

Non-Executive Director

0.04 0.0434 0.92:1 (50.00%)

8. Mr. Tomo Nagahiro#

Non-Executive Director

0.08 1.84:1 (20.00%)

9. Mr. Lim Tsin LinA

Non-Executive Director

- - -

10. Mr. Ashok Pandit#

Non-Executive Director

0.18 4.15:1 50.00%

11. Dr. Prem Kumar Nair#

Non-Executive Director

0.14 3.23:1 75.00%

12. Mr. Leo Puri***

Chairman (Independent Director)

0.55 12.67:1 NA

13. Mr. Vivek Kumar Goyal

Chief Financial Officer

5.51 126.96:1 11.42% !

14. Mr. Satyendra Chauhan

Company Secretary & Compliance Officer

1.01 23.27:1 NA$

* Annual salary paid, including taxable perquisites, excluding interest accrued on employer contributions to Provident Fund and

National Pension Scheme for prior periods, as well as reimbursements made against submitted expense bills.

# All Non-Executive Directors including Independent Directors are paid sitting fees on the basis of their attendance at the Board/ Committee Meetings. Any variation highlighted above in the remuneration of these Directors is on account of the number of meetings held or attended during the year. Further, Independent Directors were also eligible for the commission, during the period under review.

** Mr. Ravi Rajagopal resigned as Chairman & Independent Director of the Company w.e.f. September 30, 2024 and consequent to the resignation of Mr. Ravi Rajagopal as Chairman of the Company, Mr. Indrajit Banerjee was appointed as the regular Chairman of the Board, with effect from October 1, 2024, till the time vacancy is filled.

*** Mr. Leo Puri was appointed as an Additional Non-Executive Independent Director of the Company w.e.f. December 27, 2024 and had also been designated as Chairman of the Board.

$ Appointed during FY 2023-24 i.e. from March 01, 2024, hence the remuneration paid for FY 2024-25 is not comparable.

A No sitting Fee/commission paid.

@ Due to increase in commission and/or sitting fees for meetings attended.

! Increment percentage is calculated on the Total Cost To The Company (TCTC).

(b) The percentage increase in the median remuneration of employees in the financial year- 11.16%

Increases in annual CTC of active employees between the current and last financial year are considered to compute the above figure.

(c) The number of permanent employees on the roll of the Company is 3184 as on March 31, 2025, this includes the full -time retainers.

(d) Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and any exceptional circumstances for increase in the managerial remuneration **

Particulars

For the Financial Year 2024-25

(A) Average percentile increases already made in the salaries of employees other than the managerial personnel

11.54%

(B) Percentile increase in the managerial remuneration

8.71%

Comparison of (A) and (B)

+2.83%

Justification

The Company's average salary increment, excluding KMPs, is 11.54%. The percentage increment varies across job grades, with lower grades typically receiving higher increments compared to senior grades.

Additionally, market corrections are also factored into the overall increment.

Any exceptional circumstances for increase in the managerial remuneration

Not Applicable

**Percentage (%) increase in salary has been calculated by comparing the salaries of active employees as of 31/03/2025 with their salaries as of 31/03/2024, considering only those who received an increment during the year

(e) Remuneration paid to Directors and KMPs is as per the Remuneration Policy of the Company.

REMUNERATION POLICY

On the recommendation of the Nomination and Remuneration Committee, the Board has framed a policy for selecting and appointing Directors, Senior Management, and their remuneration including criteria for determining qualifications, positive attributes, independence of a Director, etc. Details of the Remuneration Policy and changes, if any, are stated in the Corporate Governance Report.

Your Company has from time to time familiarised the Board of Directors with the Company's operations, their roles, rights, responsibilities in your Company, nature of the industry in which your Company operates, business model of your Company, etc. The same is governed by a template viz Board of Directors Governance Standard and it is available on the website of the Company at https://www.fortishealthcare.com/investors/ policies-&-code/483

PARTICULARS OF EMPLOYEES

The information required pursuant to Section 197 read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of employees of your Company, will be provided upon request. In terms of Section 136 of the Companies Act, 2013, the Report and Accounts are being sent to the Members and others entitled thereto, excluding the information on employees' particulars which is available for inspection by the Members at the Registered Office and / or Corporate Office of the Company during business hours between 10.00 am to 12.00 noon on working days (Except Saturday and Sunday) of the Company up to the date of the ensuing Annual General Meeting. If any Member is interested in obtaining a copy thereof, such Member may write to the Company Secretary in this regard.

RELATED PARTY TRANSACTIONS

Disclosures as required under Section 134(3)(h) read with Rule 8(2) of the Companies (Accounts) Rules, 2014, are given in "Annexure - V" in Form AOC- 2 as specified under the Companies Act, 2013.

The Related Party Transactions are placed before the Audit Committee for approval as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Prior omnibus approval of the Audit Committee is obtained for the transactions which are of a foreseeable and repetitive nature. The transactions entered into pursuant to the omnibus approval so granted are audited and a statement giving details of all related party transactions is placed before the Audit Committee for their review on a quarterly basis. The policy on Related Party Transactions as approved by the Board is uploaded

on the Company's website at https://www.fortishealthcare. com/investors/policies-&-code/483.

None of the current Directors has any pecuniary relationship or transaction vis-a-vis your Company, except to the extent of sitting fees and remuneration/commission approved by the Board of Directors and/or shareholders of your Company and as disclosed in this Annual Report.

APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE AND DISCLOSURE ON ONE-TIME SETTLEMENT

As on the date of the Report no application is pending under the Insolvency and Bankruptcy Code, 2016 and the Company did not file any application under ('IBC') during the FY 2024-25. Further, the Company has not made any one-time settlement

RISK MANAGEMENT POLICY AND FRAMEWORK

The Company has a robust process for managing the top risks, overseen by the RMC. As part of this process, the Company has identified the risks with the highest impact and then assigned a likely probability of occurrence. Your company has also defined quantitative key risk indicators (KRIs) to monitor the effectiveness of actions take to mitigate the identified risks. Mitigation plans for each risk have also been put in place and are reviewed by the Management every six months before presenting to the RMC. The RMC has set out a review process to report to the Board on the progress of the initiatives for the major risks of each of the businesses.

POLICY FOR PREVENTION, PROHIBITION AND REDRESSAL OF SEXUAL HARASSMENT

Your Company has adopted a Policy for Prevention, Prohibition and Redressal of Sexual Harassment. As per the requirement of the Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013 and Rules made thereunder, your Company has constituted Internal Complaints Committees (ICC). During the Financial Year 2024-25, your Company has received 7 complaints on sexual harassment and all 7 complaints have been resolved with appropriate action taken and no complaint was pending as on March 31, 2025.

DISCLOSURE REQUIREMENTS

As per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Corporate Governance Report with Auditors' certificate thereon are attached, which forms part of this report.

Further, pursuant to the provisions of Section 143(12) of the Companies Act 2013, neither the Statutory Auditors nor the Secretarial Auditors & Cost Auditors have reported any incident of Fraud to the Audit Committee or the Board during the period under review.

CODE OF CONDUCT

Declaration by Dr. Ashutosh Raghuvanshi, Managing Director and Chief Executive Officer confirming compliance with the 'Fortis Code of Conduct' is enclosed with Corporate Governance Report.

CERTIFICATE BY STATUTORY AUDITORS FOR DOWNSTREAM INVESTMENT

A certificate from the Statutory Auditors of your Company stating that your Company has duly complied with the requirements of downstream investment made by your Company to second level entities in accordance with Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, 2017 would be available at the Annual General Meeting for inspection by members.

DIRECTORS' RESPONSIBILITY STATEMENT

To the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors make the following statements in terms of Section 134(3)(c) of the Companies Act, 2013:

(a) In the preparation of the Annual Accounts, the applicable accounting standards have been followed along with proper explanations relating to material departures therefrom, if any;

(b) They had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of your Company at the end of the financial year and of the profit of your company for the Financial year ended March 31, 2025;

(c) Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of your Company and for preventing and detecting fraud and other irregularities;

(d) The annual accounts have been prepared on a going concern basis;

(e) Proper internal financial controls have been laid down and that such internal financial controls were adequate and were operating effectively; and

(f) There are proper systems in place to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

ACKNOWLEDGEMENT

Your Directors place on record their gratitude to the Central Government, State Governments and all other Government agencies for the assistance, co-operation and encouragement they have extended to the Company. Your Directors also take this opportunity to extend a special thanks to the medical fraternity and patients for their continued cooperation, patronage and trust in the Company.

Your Directors are glad to place on record that your Company has posted a strong financial performance during the year and greatly appreciate the commitment and dedication of all the employees, that has contributed to the growth and success of the Company. Your Directors also thank all the strategic partners, business associates, Debenture Trustee/Holders Banks, financial institutions for their assistance, co-operation and encouragement to the Company during the year.

Last but not the least your Directors thank the Shareholders of the Company for their continued faith in the Company.

By Order of the Board of Directors

For Fortis Healthcare Limited

Sd/-

Sd/-

Dr. Ashutosh Raghuvanshi

Leo Puri

Managing Director and Chief Executive Officer

Chairman (Independent Director)

DIN: 02775637

DIN: 01764813

Date: May 20, 2025

Place: Gurugram